We believe that unraveling the genetic network of CDK1 (i.e. the network of genes that become essential under conditions of reduced Cdk1 activity) might identify novel pathways that can be targeted by combination therapy with CDK inhibitors to induce synthetic lethality of cancer cells, thus contributing to more personalized, less toxic and more efficacious chemotherapy. Here, CDK1 is linked to cancer.